IPSC0125, AJG001-C4
The cell line is not validated yet.
CBIGi001-C
General
Cell Line |
|
| hPSCreg name | CBIGi001-C |
| Cite as: | CBIGi001-C |
| Alternative name(s) |
IPSC0125, AJG001-C4
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi001-A (AIW002-02, IPSC0063) CBIGi001-B (IPSC0064) CBIGi001-A-11 (IPSC0075, PRKN Y143D/AIW002-02) CBIGi001-A-44 (IP6K2-KO/AIW002-02, IPSC0116) CBIGi001-A-12 (PRKN-V393D/AIW002-02, IPSC0076) CBIGi001-A-13 (IPSC0078, SCARB2-KO/AIW002-02) CBIGi001-A-14 (IPSC0079, SH3GL2-KO/AIW002-02) CBIGi001-A-45 (LRRK2-KO/AIW002-02, IPSC0117) CBIGi001-A-15 (SNCA A30P/AIW002-02, IPSC0080) CBIGi001-A-16 (IPSC0081, SNCA A53T/AIW002-02) CBIGi001-A-17 (IPSC0082, SNCA E46K/AIW002-02) CBIGi001-A-18 (IPSC0083, SNCA-KO/AIW002-02) CBIGi001-A-19 (IPSC0084, SOD1 G93A/AIW002-02) CBIGi001-A-20 (SPG11-KO/AIW002-02, IPSC0085) CBIGi001-A-21 (IPSC0086, SMPD-KO/AIW002-02) CBIGi001-A-22 (TARDBP-A382T/AIW002-02, IPSC0089) CBIGi001-A-23 (TARDBP-G348C/AIW002-02, IPSC0090) CBIGi001-A-24 (TMEM163-KO/AIW002-02, IPSC0096) CBIGi001-A-25 (IPSC0097, TMEM175-KO/AIW002-02) CBIGi001-A-1 (PRKN-KO, PRKN-KO/AIW002-02, IPSC0070) CBIGi001-A-26 (USP19-KO/AIW002-02, IPSC0098) CBIGi001-A-27 (IPSC0099, ARL13B-KO/AIW002-02) CBIGi001-A-28 (IPSC0100, ASAH1-KO/AIW002-02) CBIGi001-A-29 (ATAXIN3-KO/AIW002-02, IPSC0101) CBIGi001-A-2 (PINK1-KO, PINK1-KO/AIW002-02, IPSC0072) CBIGi001-A-3 (PINK1-KO/PRKN-KO/AIW002-02, PINK1-KO/PRKN-KO, IPSC0069) CBIGi001-A-30 (BIN3-KO/AIW002-02, IPSC0102) CBIGi001-A-31 (IPSC0103, C9ORF72-KO/AIW002-02) CBIGi001-A-32 (CDH12-KO/AIW002-02, IPSC0104) CBIGi001-A-33 (CLCN3-KO/AIW002-02, IPSC0105) CBIGi001-A-34 (CTSB-KO/AIW002-02, IPSC0106) CBIGi001-A-35 (FAM49B(CYRIB)-KO/AIW002-02, IPSC0107) CBIGi001-A-36 (IPSC0108, FMR1-KO/AIW002-02) CBIGi001-A-4 (MAPT P301L/AIW002-02, IPSC0065) CBIGi001-A-37 (IPSC0109, FUS-H517Q/AIW002-02) CBIGi001-A-5 (MAPT-KO/AIW002-02, IPSC0066) CBIGi001-A-38 (IPSC0110, FUS-KO/AIW002-02) CBIGi001-A-6 (IPSC0067, OFD1-KO/AIW002-02) CBIGi001-A-39 (IPSC0111, GALC-KO/AIW002-02) CBIGi001-A-7 (IPSC0068, OPTN-KO/AIW002-02) CBIGi001-A-40 (IPSC0112, GBA-KO/AIW002-02) CBIGi001-A-8 (IPSC0071, PINK1-3flag/AIW002-02) CBIGi001-A-41 (IPSC0113, GBAP1_promoter-KO/AIW002-02) CBIGi001-A-9 (IPSC0073, PRKN A401D/AIW002-02) CBIGi001-A-42 (IGSF9B-KO/AIW002-02, IPSC0114) CBIGi001-A-10 (IPSC0074, PRKN W403A/AIW002-02) CBIGi001-A-43 (INPP5F-KO/AIW002-02, IPSC0115) |
| Last update | 25th July 2025 |
| User feedback | |
Provider |
|
| Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA118002769 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
Donor Information
General Donor Information |
|
| Sex | male |
| Ethnicity | Caucasian |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA12565539 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| * Does consent expressly prevent the derivation of pluripotent stem cells? | No |
| * Does consent pertain to a specific research project? | No |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
| an academic institution? | Yes |
| a public organisation? | Yes |
| a non-profit company? | Yes |
| a for-profit corporation? | Yes |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | McGill University Health Centre Research Ethics Board (MUHC REB) |
| Approval number | C-BIG(MUHC-15-944) (CRU) |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Passage number reprogrammed | P9 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal 46, XY
Passage number: P9
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.